Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following drugs does not concentrate in bile?

Alpha methyl dopa. ***Alpha methyl dopa*** - **Alpha methyl dopa** is primarily excreted by the kidneys and does not undergo significant biliary excretion or concentration in bile. - Its concentration in bile is negligible compared to other drugs known for biliary excretion. *Erythromycin* - **Erythromycin** is well-known for its significant biliary excretion and concentration in bile. - This characteristic can lead to drug interactions and cholestasis in some patients due to its processing in the liver. *Tetracycline* - **Tetracycline** antibiotics, including tetracycline itself, are excreted extensively in bile. - **Enterohepatic recirculation** is a common phenomenon with tetracyclines, contributing to their prolonged half-life. *Oral contraceptives* - Many components of **oral contraceptives**, particularly estrogen metabolites, undergo extensive hepatic metabolism and enterohepatic recirculation, leading to their concentration in bile. - The biliary excretion of these compounds is a key factor in their pharmacokinetic profile and drug interactions.

Q: Assuming the half-life of gentamicin is 3 hours in this patient, what percentage of the initial dose is most likely to remain in the body 6 hours later?

25%. ***25%*** - After **one half-life** (3 hours), 50% of the initial dose remains. - After **two half-lives** (6 hours), 25% of the initial dose remains (50% of the remaining 50%). *12.5%* - This percentage would remain after **three half-lives** (9 hours), not 6 hours. - Each half-life reduces the remaining drug by 50%, so 50% -> 25% -> 12.5%. *33%* - This value does not correspond to a direct calculation based on the given half-life. - The drug concentration would decrease by a factor of 4 (100% to 25%) over two half-lives. *50%* - This percentage would remain after **one half-life** (3 hours), not 6 hours. - The question asks for the amount remaining after two half-lives have passed.

Q: Which of the following drugs is metabolized by CYP2D6?

Propranolol. ***Correct Answer: Propranolol*** - **Propranolol** is a non-selective beta-blocker that undergoes extensive **first-pass metabolism**, primarily via the **CYP2D6** and CYP1A2 enzymes. - Genetic variations in **CYP2D6** can significantly affect propranolol's metabolism, leading to altered drug levels and therapeutic responses. *Incorrect: Warfarin* - **Warfarin** is predominantly metabolized by **CYP2C9**, with minor contributions from other CYP enzymes. - Genetic polymorphisms in **CYP2C9** are a major factor in determining individual warfarin dose requirements. *Incorrect: Statins* - Most **statins** (e.g., simvastatin, lovastatin, atorvastatin) are primarily metabolized by **CYP3A4**. - **Fluvastatin** is an exception, being mainly metabolized by CYP2C9, while **rosuvastatin** is largely unmetabolized. *Incorrect: Amiodarone* - **Amiodarone** is primarily metabolized by **CYP3A4** and to a lesser extent by CYP2C8. - Due to its **long half-life** and extensive metabolism, amiodarone has numerous drug interactions, often involving CYP3A4 inhibition.

Q: Forced diuresis with acidification or alkalinization of urine is a common method for elimination of certain poisons/drugs from the body. The elimination of which of the following drugs is commonly enhanced by alkaline diuresis?

Phenobarbitone. ***Phenobarbitone*** - **Alkaline diuresis** enhances the elimination of weak acids like **phenobarbitone** by keeping them in their ionized form within the renal tubules, preventing reabsorption. - Ionized drugs are more water-soluble and are thus efficiently excreted in the urine. *Amphetamines* - **Amphetamines** are **weak bases**, and their elimination is enhanced by **acidification of urine**, which ionizes them and reduces their reabsorption. - Alkaline diuresis would not be effective, and might even hinder, the elimination of amphetamines. *Theophylline* - Theophylline is primarily metabolized in the liver, and its renal excretion is less influenced by urinary pH manipulation. - While it behaves as a weak acid, forced diuresis is not a primary method for its elimination in overdose situations. *Phencyclidine* - **Phencyclidine (PCP)** is a **weak base**, and its elimination is increased by **acidification of urine**, similar to amphetamines. - Alkaline diuresis would decrease the excretion of phencyclidine.

Q: What does the time for peak plasma concentration (Tmax) indicate?

The rate of absorption. ***The rate of absorption*** - **Tmax** is the time at which the **maximum drug concentration** in the plasma is reached [1]. - A shorter **Tmax** indicates a faster rate at which the drug is absorbed from its administration site into the systemic circulation [1]. *The rate of elimination* - The rate of elimination is primarily reflected by the **elimination half-life (t½)** of the drug, which is the time it takes for the plasma concentration to decrease by half. - While Tmax is influenced by both absorption and elimination, it does not directly indicate the elimination rate [1]. *The duration of effect* - The **duration of effect** is related to how long the drug concentration remains above the minimum effective concentration (MEC), which is influenced by both absorption and elimination, but not directly indicated by Tmax alone. - A drug's duration of action is better described by its **elimination half-life** and the **therapeutic window**. *The intensity of effect* - The **intensity of effect** is largely related to the **maximum plasma concentration (Cmax)** and the drug's affinity for its target, and not directly by the time it takes to reach that concentration. - **Cmax** indicates how much drug is in the bloodstream, which often correlates with the intensity of the pharmacological response.

Q: What does ED50 measure in pharmacology?

Potency. ***Potency*** - **ED50** (Effective Dose 50%) is the dose of a drug that produces a **therapeutic effect** in 50% of the population or the maximum effect in 50% of subjects [3, 4]. - It is a key measure of a drug's **potency**: a lower ED50 indicates higher potency [1, 3]. *Toxicity* - **Toxicity** is primarily measured by **LD50** (Lethal Dose 50%), which indicates the dose at which 50% of the population would die [3, 4]. - While related to drug safety, ED50 does not directly quantify toxicity. *Safety* - **Safety** is evaluated using the **therapeutic index**, which ideally compares the **TD50** (Toxic Dose 50%) or **LD50** to the ED50 [3, 4]. - ED50 alone measures effectiveness, not the margin between effective and toxic doses. *Efficacy* - **Efficacy** refers to the **maximal response** a drug can produce, regardless of the dose [1]. - A drug with high efficacy might have a high or low ED50, as efficacy is about the *height* of the effect, not the *dose* at which it occurs [1].

Q: Which of the following statements about drug distribution in tissues is NOT true?

Ephedrine - bone. ***Ephedrine - bone*** - This statement is **NOT true**. **Ephedrine** is a sympathomimetic amine that does not have clinically significant accumulation in **bone tissue**. - While ephedrine distributes to various tissues due to its physicochemical properties, there is **no established evidence** of preferential or significant bone accumulation that is clinically relevant. - Unlike the other drug-tissue pairs listed, this pairing lacks strong pharmacokinetic evidence. *Chloroquine - eye* - This statement is **true**. **Chloroquine** (and hydroxychloroquine) accumulates significantly in the **retina** and **cornea**, leading to **retinal toxicity** (e.g., bull's eye maculopathy) with chronic use. - Ocular side effects are a significant concern with long-term chloroquine therapy, necessitating regular **ophthalmological monitoring**. *Minocycline - adipose tissue* - This statement is **true**. **Minocycline** is a highly **lipophilic tetracycline** that accumulates significantly in **adipose tissue**. - Its high lipid solubility allows extensive tissue distribution, including fat stores, contributing to its **prolonged elimination half-life** (15-23 hours). - This lipophilicity also enables excellent CNS penetration and wide tissue distribution. *Digoxin - skeletal muscle* - This statement is **true**. **Digoxin** has a large volume of distribution (5-7 L/kg) primarily due to its significant binding to **skeletal muscle** and **cardiac muscle**, where it exerts its therapeutic effects. - Its accumulation in skeletal muscle contributes to its prolonged **elimination half-life** and wide distribution pattern.

Q: The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.

Ratio of toxic dose to effective dose. ***Ratio of toxic dose to effective dose***- The **therapeutic index (TI)** is quantitatively defined as the ratio of the toxic dose (TD50 or LD50) to the effective dose (ED50) [1, 2].- This ratio provides a measure of **drug safety**, indicating the range between the therapeutic and toxic concentrations [1, 3].*Margin of safety*- While related to safety, the **margin of safety** is a different concept, often calculated as (TD1 - ED99) / ED99, focusing on the overlap between very few people experiencing toxicity and almost everyone receiving benefit [2].- The therapeutic index is a broader, simpler ratio that doesn't explicitly guarantee overlap safety but indicates overall drug risk.*Efficacy of the drug*- **Efficacy** refers to the maximal effect a drug can produce regardless of the dose, and it is independent of the therapeutic index [2].- A drug can have high efficacy but a narrow therapeutic index, meaning it is very effective but also very toxic at doses slightly above the therapeutic range.*Drug potency*- **Potency** is the amount of drug needed to produce a given effect (e.g., ED50), reflecting its affinity for receptors and efficiency of action [2].- It is distinct from the therapeutic index, which assesses the separation between desired and undesired effects, not the concentration required to achieve a therapeutic effect.

Q: Which of the following causes an increase in cAMP levels?

Beta (β) receptor. ***Beta (β) receptor*** - **Beta-adrenergic receptors** (β1, β2, β3) are G-protein coupled receptors that, when activated, couple to **Gs proteins**, leading to the activation of **adenylyl cyclase**. - **Adenylyl cyclase** then catalyzes the conversion of **ATP to cAMP**, thereby increasing intracellular cAMP levels and triggering downstream signaling pathways. *Alpha (α) receptor* - **Alpha-1 adrenergic receptors** (α1) typically couple to **Gq proteins**, leading to the activation of **phospholipase C**, which increases **intracellular calcium** and activates protein kinase C, not cAMP. - **Alpha-2 adrenergic receptors** (α2) couple to **Gi proteins**, which inhibit adenylyl cyclase, thereby **decreasing cAMP levels**. *Somatostatin* - **Somatostatin receptors** are G-protein coupled receptors that primarily couple to **Gi proteins**. - Activation of **Gi proteins** leads to the **inhibition of adenylyl cyclase**, resulting in a **decrease in cAMP levels**. *Acetylcholine* - **Acetylcholine** acts on **muscarinic** and **nicotinic receptors**. Muscarinic receptors (M2 and M4) couple to **Gi proteins**, which **decrease cAMP production**. - Other muscarinic receptors (M1, M3, M5) couple to **Gq proteins**, leading to increased **intracellular calcium**, not cAMP.

Q: Phase 1 biotransformation includes

Reduction. ***Reduction*** - **Phase 1 biotransformation reactions** are non-synthetic reactions that introduce or expose polar functional groups (e.g., -OH, -NH2, -SH) on xenobiotics to make them more water-soluble. - The three main Phase 1 reactions are **oxidation**, **reduction**, and **hydrolysis**. - These reactions typically involve **cytochrome P450 enzymes** and prepare drugs for excretion or Phase 2 conjugation. *Acetylation* - **Acetylation** is a **Phase 2 (conjugation) reaction**, not Phase 1. - Involves transfer of an acetyl group to amine-containing drugs via **N-acetyltransferase**. - Increases water solubility and facilitates excretion. *Sulfate conjugation* - **Sulfate conjugation** is a **Phase 2 (conjugation) reaction**, not Phase 1. - Involves addition of a sulfate group via **sulfotransferase enzymes**. - Significantly increases hydrophilicity for renal excretion. *Methylation* - **Methylation** is a **Phase 2 (conjugation) reaction**, not Phase 1. - Involves addition of a methyl group via **methyltransferase enzymes**. - Unlike most Phase 2 reactions, methylation may sometimes **decrease** water solubility but is still classified as conjugation.

Question 1

Which of the following drugs does not concentrate in bile?

Accepted Answer

Alpha methyl dopa

Answer

Erythromycin

Answer

Tetracycline

Answer

Oral contraceptives

Question 2

Assuming the half-life of gentamicin is 3 hours in this patient, what percentage of the initial dose is most likely to remain in the body 6 hours later?

Accepted Answer

25%

Answer

12.5%

Answer

33%

Answer

50%

Question 3

Which of the following drugs is metabolized by CYP2D6?

Accepted Answer

Propranolol

Answer

Warfarin

Answer

Statins

Answer

Amiodarone

Question 4

Forced diuresis with acidification or alkalinization of urine is a common method for elimination of certain poisons/drugs from the body. The elimination of which of the following drugs is commonly enhanced by alkaline diuresis?

Accepted Answer

Phenobarbitone

Answer

Amphetamines

Answer

Theophylline

Answer

Phencyclidine

Question 5

What does the time for peak plasma concentration (Tmax) indicate?

Accepted Answer

The rate of absorption

Answer

The rate of elimination

Answer

The duration of effect

Answer

The intensity of effect

Question 6

What does ED50 measure in pharmacology?

Accepted Answer

Potency

Answer

Toxicity

Answer

Safety

Answer

Efficacy

Question 7

Which of the following statements about drug distribution in tissues is NOT true?

Accepted Answer

Ephedrine - bone

Answer

Minocycline - adipose tissue

Answer

Digoxin - skeletal muscle

Answer

Chloroquine - eye

Question 8

The therapeutic index of a drug is defined as the ratio between the toxic dose and the effective dose.

Accepted Answer

Ratio of toxic dose to effective dose

Answer

Margin of safety

Answer

Efficacy of the drug

Answer

Drug potency

Question 9

Which of the following causes an increase in cAMP levels?

Accepted Answer

Beta (β) receptor

Answer

Alpha (α) receptor

Answer

Somatostatin

Answer

Acetylcholine

Question 10

Phase 1 biotransformation includes

Accepted Answer

Reduction

Answer

Methylation

Answer

Acetylation

Answer

Sulfate conjugation

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?